Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)

2023

Kalinsky K, Spring L, Yam C, Taylor A, Sjekloca N, Kaushiva A, Lai C, Ntalla I, Nanda R